Skip to main content

Advertisement

SpringerLink
Log in

Different Survival Benefits of Chinese Medicine for Pancreatic Cancer: How to Choose?

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To assess the efficacy of Chinese medicine (CM) on patients with pancreatic cancer (PC) in a retrospective population-based study.

Methods

Between January 1, 2013, and August 30, 2016, according to whether received Western medicine treatment, the patients were included into either integrative medicine (IM) group or CM group. All enrolled patients were orally administrated with Gexia Zhuyu Decoction (膈下逐瘀汤) or Liujun Ermu Decoction (六君二母汤) by syndrome differentiation, twice a day, last for at least 2 months. The primary end point was overall survival (OS).

Results

A total of 174 patients with PC were enrolled in this study. In stage I/II, the median OS was 20.5 months in the IM group [95% confidence interval (CI), 12.499 to 28.501] and 11.17 months in the CM group (95% CI, 5.160 to 17.180, P=0.015). The 1- and 2-year survival rates for the two groups were 47.0%, 40.0% and 21.0%, 21.0%, respectively. In stage III/IV, median OS was 13.53 months (95% CI, 8.665 to 18.395) in the IM group versus 6.4 months (95% CI, 0.00 to 15.682) in the CM group, respectively (P=0.32). The 1- and 2-year survival rate for the IM and CM groups were 27.0%, 7.0% and 20.0%, 2.0%, respectively.

Conclusions

Intervention of CM contributes to the different survival benefits for PC in different stages. Multimodality treatment might be a promising strategy for PC patients in early stage. While, in advanced stage, CM might be an alternative candidate for PC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2016;66:7–30.

    Article  PubMed  Google Scholar 

  2. Yang GY, Wagner TD, Fuss M, Thomas CR Jr. Multimodality approaches for pancreatic cancer. CA Cancer J Clin 2005;55:352–367.

    Article  PubMed  Google Scholar 

  3. Xue T. Synergy in traditional Chinese medicine. Lancet Oncol 2016;17:e39.

    Article  Google Scholar 

  4. Lee YW, Chen TL, Shih YR, Tsai CL, Chang CC, Liang HH, et al. Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: a population-based study. Cancer 2014;120:1338–1344.

    Article  PubMed  Google Scholar 

  5. Xu Y, Zhao AG, Li ZY, Zhao G, Cai Y, Zhu XH, et al. Survival benefit of traditional Chinese herbal medicine (a herbal formula for invigorating Spleen) for patients with advanced gastric cancer. Integr Cancer Ther 2013;12:414–422.

    Article  PubMed  Google Scholar 

  6. Yang X, Hao J, Zhu CH, Niu YY, Ding XL, Liu C, et al. Survival benefits of Western and traditional Chinese medicine treatment for patients with pancreatic cancer. Medicine (Baltimore) 2015;94:e1008.

    Article  Google Scholar 

  7. Yao DP. The research on syndromes distribution of pancreatic cancer [dissertation]. Beijing: Beijing University of Chinese Medicine; 2015.

    Google Scholar 

  8. Zhang J, Wang P, Liu LM. Analyzing the TCM syndromes of pancreatic cancer. China J Tradit Chin Med Pharm (Chin) 2012;27:579–581.

    Google Scholar 

  9. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–132.

    Article  PubMed  Google Scholar 

  10. Wagner M, Dikopoulos N, Kulli C, Friess H, Buchler MW. Standard surgical treatment in pancreatic cancer. Ann Oncol 1999;10(Suppl 4):247–251.

    Article  PubMed  Google Scholar 

  11. Johnston WC, Hoen HM, Cassera MA, Newell PH, Hammill CW, Hansen PD, et al. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base. HPB (Oxford) 2016;18:21–28.

    Article  Google Scholar 

  12. Nentwich MF, Konig A, Izbicki JR. Limits of surgery for pancreatic cancer. Rozhl Chir 2014;93:445–449.

    CAS  PubMed  Google Scholar 

  13. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009;101:908–915.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073–1081.

    Article  CAS  PubMed  Google Scholar 

  15. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer. JAMA 2013;310:1473.

    Article  CAS  PubMed  Google Scholar 

  16. Ellenrieder V, Konig A, Seufferlein T. Current standard and future perspectives in first- and second-line treatment of metastatic pancreatic adenocarcinoma. Digestion 2016;94:44–49.

    Article  CAS  PubMed  Google Scholar 

  17. Zafar SF, El-Rayes BF. Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma. Am J Clin Oncol 2014;37:194–200.

    Article  CAS  PubMed  Google Scholar 

  18. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605–1617.

    Article  CAS  PubMed  Google Scholar 

  19. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–2413.

    Article  CAS  PubMed  Google Scholar 

  20. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513–5518.

    Article  CAS  PubMed  Google Scholar 

  21. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteni G, Massidda B, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28:1645–1651.

    Article  CAS  PubMed  Google Scholar 

  22. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617–3622.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Vaccaro V, Sperduti I, Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;365:768–769; author reply 9.

    Article  CAS  PubMed  Google Scholar 

  24. Goncalves A, Gilabert M, Francois E, Dahan L, Perrier H, Lamy R, et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012;23:2799–2805.

    Article  CAS  PubMed  Google Scholar 

  25. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–1703.

    Article  Google Scholar 

  26. Ioka T, Okusaka T, Ohkawa S, Boku N, Sawaki A, Fujii Y, et al. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized phase III trial. Jpn J Clin Oncol 2015;45:439–448.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Wang WJ, Wu MY, Shen M, Zhi Q, Liu ZY, Gong FR, et al. Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the beta-catenin pathway and strengthen the cytotoxicity of gemcitabine and erlotinib. Int J Oncol 2015;47:1912–1922.

    Article  CAS  PubMed  Google Scholar 

  28. Pan FP, Zhou HK, Bu HQ, Chen ZQ, Zhang H, Xu LP, et al. Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK. Oncol Rep 2016;35:1941–1949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Zhou ZG, Zhang CY, Fei HX, Zhong LL, Bai Y. Phenolic alkaloids from Menispermum dauricum inhibits BxPC-3 pancreatic cancer cells by blocking of Hedgehog signaling pathway. Pharm Mag 2015;11:690–697.

    Article  CAS  Google Scholar 

  30. Xu Y, Zhu F, Xu S, Liu L. Anti-tumor effect of the extract from Qingyihuaji Formula on pancreatic cancer by down-regulating Notch-4 and Jagged-1. J Tradit Chin Med 2015;35:77–83.

    Article  PubMed  Google Scholar 

  31. Xu L, Li H, Xu Z, Wang Z, Liu L, Tian J, et al. Multicenter randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. BMC Complement Altern Med 2012;12:112.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Lin SZ, Xu JB, Ji X, Chen H, Xu HT, Hu P, et al. Emodin inhibits angiogenesis in pancreatic cancer by regulating the transforming growth factor-beta/drosophila mothers against decapentaplegic pathway and angiogenesis-associated microRNAs. Mol Med Rep 2015;12:5865–5871.

    Article  CAS  PubMed  Google Scholar 

  33. Liu Y, Zhang W, Wang XJ, Liu S. Antitumor effect of Kanglaite Injection in human pancreatic cancer xenografts. BMC Complement Altern Med 2014;14:228.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China

    Meng Li, Miao-miao Wang, Xiu-wei Guo, Dao-rui Li & Pei-tong Zhang

  2. Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China

    Meng Li, Miao-miao Wang, Chao-yong Wu & Xing Zhang

Authors
  1. Meng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miao-miao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiu-wei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chao-yong Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dao-rui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pei-tong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pei-tong Zhang.

Additional information

Supported by the National Natural Science Foundation of China (No. 81673797)

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, M., Wang, Mm., Guo, Xw. et al. Different Survival Benefits of Chinese Medicine for Pancreatic Cancer: How to Choose?. Chin. J. Integr. Med. 24, 178–184 (2018). https://doi.org/10.1007/s11655-017-2971-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-017-2971-1

Keywords

Search

Navigation